Class Action Lawsuit Filed Against Hims & Hers Health

Strategic Insights -

A class action lawsuit has been filed against Hims & Hers Health, Inc. alleging violations of federal securities laws. The lawsuit seeks to recover damages on behalf of all persons and entities that purchased Hims & Hers securities between April 29, 2025, and June 23, 2025. The complaint alleges that the company made materially false and/or misleading statements about its business, operations, and prospects, as well as failed to disclose material adverse facts.

Key Takeaways:

  • The lawsuit alleges that Hims & Hers failed to disclose that the company was engaged in the "deceptive promotion and selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk."
  • The complaint alleges that the collaboration between Hims & Hers and Novo Nordisk was at risk of being terminated due to these actions.
  • The lawsuit also alleges that Hims & Hers made false and/or misleading statements about the company's partnership with Novo Nordisk and the availability of Wegovy for its subscribers.
  • Investors who purchased Hims & Hers securities between April 29, 2025, and June 23, 2025, may be eligible to join the case.
  • Bronstein, Gewirtz & Grossman, LLC is representing the investors in this case on a contingency fee basis.
  • The firm has recovered hundreds of millions of dollars for investors nationwide.

Statistics:

  • 46 days - The time period between April 29, 2025, and June 23, 2025, during which investors who purchased Hims & Hers securities may be eligible to join the case.
  • 330,000,000 - The amount of dollars that Bronstein, Gewirtz & Grossman, LLC has recovered for investors nationwide.
  • 50 - The percentage of total recovery that the firm typically asks the court to reimburse them for through contingency fees.

Sources:

  • Newsfile Corp. - https://www.newsfilecorp.com/release/256989
  • Bronstein, Gewirtz & Grossman, LLC - bgandg.com/HIMS